Biomedical subjects

H Minato

Publications and source records attributed to H Minato.

113 records · Page 7Linked to original sources

PubMedDate not supplied

Adenocarcinoma in situ of the fallopian tube. A case report.

BACKGROUND: So far only a few cases of carcinoma in situ of the fallopian tube have been reported, but its detailed clinical and pathologic findings, including cytology, have not been fully described. CASE: A 70-year-old female was admitted to our hospital because of irregular genital bleeding. Endometrial smear revealed a small number of atypical cells with a clear background. Hysterectomy, bilateral salpingo-oophorectomy and omentectomy were performed. Grossly, a grayish white papillary tumor, measuring 1.5 x 1.0 cm, was observed within the lumen of the left fallopian tube. Microscopically, the diagnosis of papillary adenocarcinoma in situ of the left fallopian tube was made according to 1992 International Federation of Gynecologists and Obstetricians fallopian tube staging. CONCLUSION: Although endometrial brush cytology is not sensitive enough to detect a primary carcinoma of the fallopian tube, our case indicates that it may contribute useful information on extrauterine diseases and can detect a stage 0 cancer of the fallopian tube. Clinicians, as well as pathologists, should consider the possibility of fallopian tube cancer if cervical or endometrial cytology shows atypical cells with papillary patterns with a clear background but endometrial curettage cannot prove malignancy.

Adenocarcinoma↗

PubMedDate not supplied

Tumor size and extension of lymph node metastases in N2 lung cancer.

In all patients with NSCLC, systematic nodal dissection was performed. Since 1981, 218 stage IIIA-N2 cases were resected. We registered 2 operative mortalities. Overall survival was 23% while, in completely resected cases, survival amounted to 30%. For long-term survival, favourable prognostic factors were cN2 T1-2 N2M0, single mediastinal node involvement and a tumor 20 mm or less in maximum size. The 5 yr survival rates of stage IIIA N2 patients was, respectively 48.1% with tumor diameter < 20 mm, 27.7% with diameter between 21-30 mm, 31.2% with diameter between 31-50 mm and, finally, 16.7% with tumors larger than 51 mm. When micrometastases to lymph nodes in p-stage I (stained with H-E) were examined with immunohistochemical staining, 27% (36 patients of 132) showed micrometastases.

Carcinoma, Non-Small-Cell Lung↗

PubMedDate not supplied

Immunohistochemical detection of cytokeratin 18 and its neo-epitope in Warthin's tumor (adenolymphoma) of the parotid glands.

An immunohistochemical method using a monoclonal antibody M30 (MAb M30), which reacts with the product released by cleavage of cytokeratin 18 (CK18) by activated caspase, was used to investigate the presence and extent of apoptosis in 36 cases of Warthin's tumor (WT) of the parotid glands. The distribution of CK18 in WT was also determined and compared with that of the product detected by MAb M30. In WT, CK18 was observed mainly in the tumor cells of duct-like structures, but not in the cells of lymphatic tissues. Positive MAb M30 reaction products were found in luminal contents, duct-like structures and the cytoplasm of some macrophages in lymphatic areas near the duct-like structures in WT. These findings indicated that apoptotic cells are phagocytosed and eliminated as waste by macrophages. It is suggested that a mechanism which regulates the balance of proliferative activity and apoptosis may be closely linked to the growth of WT.

Adenolymphoma↗

PubMedDate not supplied

Antihypertensive activity of cadralazine in experimental hypertensive rats.

Antihypertensive and tachycardic activities of cadralazine were examined in experimental hypertensive rats (spontaneous, renal and deoxycorticosterone acetate-salt hypertension) after single or repeated oral administration, and compared with those of hydralazine. In single oral administration, cadralazine (0.3-5 mg/kg) produced a dose-related hypotensive effect and its maximum activity was equipotent to or more potent than that of hydralazine (1-5 mg/kg) in these hypertensive rats. The hypotensive effect of cadralazine appeared gradually and reached a maximum at 5-7 hr, while the maximum effect of hydralazine was observed at 1 hr after dosing. In SHR, the significant hypotensive effect of cadralazine persisted for 9-24 hr, but that of hydralazine lasted for only 1-12 hr. Therefore, there were marked differences in onset and duration of the hypotensive effect between cadralazine and hydralazine. Both drugs produced a dose-related tachycardic effect concomitant with the hypotensive effect. The separation ratios of cadralazine on these effects were equivalent to those of hydralazine. In repeated oral administration for 7 days, cadralazine (3 mg/kg/once a day) significantly reduced the daily starting blood pressure. The same response was obtained by 3 times daily repeated administration of hydralazine (3 mg/kg). Tolerance to the hypotensive and tachycardic effects was not observed during successive dosings of cadralazine or hydralazine. The potent and long lasting hypotensive effect of cadralazine might be useful for the treatment of arterial hypertension.

Animals↗

PubMedDate not supplied

Studies on the effects of endothelin-1 (ET-1) and endothelin-3 (ET-3) in brain hypoxia and on the participation of brain prostanoids in their actions.

The effects of endothelin-1 (ET-1) and endothelin-3 (ET-3) in brain hypoxia have been studied in mice using the following experimental models: hypobaric hypoxia induced by low atmospheric pressure, histotoxic hypoxia induced by 12.5 mg/kg KCN i.p., and complete ischemia induced by decapitation. ET-1 and ET-3 were injected intracerebroventricularly (i.c.v.) 15 min before the tests. Forebrain tissue concentrations of 6-keto-PGF1 alpha and thromboxane B2 (TxB2) were measured 15 min following i.c.v. administration of ET-1 (5 pmol/mouse) and ET-3 (10 pmol/mouse). ET-1 (1-5 pmol/mouse) and ET-3 (5-25 pmol/mouse) showed a dose-dependent increase in the survival/gasping time in all models of hypoxia. The effect reached its maximum between 15 and 30 min after ET administration and lasted for about 120 min. ET-1 and ET-3 did not significantly change the brain levels of 6-keto-PGF1 alpha and TxB2. The protective effect of ET-1 and ET-3 was unexpected, because endothelins (ETs) are the most potent vasoconstrictors known, and in doses close to those used in this study they cause vasoconstriction and decrease in cerebral blood flow. The protection was not likely to be due either to stimulation of the endogenous release of prostacyclin (PGI2) or to a decrease in the deleterious prostanoid thromboxane A2 (TxA2). Additional experiments are necessary to explain the cerebroprotective effects of ET-1 and ET-3.

Animals↗